Business Context and Reporting Period
This Form 8-K Current Report was filed by GoodRx Holdings, Inc. on June 27, 2023. The report addresses a specific corporate governance event regarding the departure of a senior executive and the appointment of a successor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Executive Departure: Babak Azad will cease serving as Chief Marketing Officer (CMO), effective July 7, 2023.
- Executive Appointment: Andrew Slutsky, currently Senior Vice President of Strategic Marketing Innovation, will assume the role of Chief Marketing Officer on the effective date.
- Role Scope: Mr. Slutsky's updated CMO role will include a more specific focus on certain marketing programs and initiatives.
Guidance, Outlook, and Risks
The Company expects to enter into a Separation Agreement with Mr. Azad. The material terms of this agreement are not disclosed in this filing and will be reported in a subsequent Current Report on Form 8-K. No financial guidance, outlook, or specific risk factors were disclosed in this document.
Investor Verification Checklist
- Verify the terms of the Separation Agreement with Babak Azad in the subsequent Form 8-K filing.
- Monitor future filings for details on the specific marketing initiatives under Andrew Slutsky's leadership.
- Review the most recent 10-Q or 10-K for current financial performance metrics, as they are absent from this report.